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Endothelial lipase (LIPG) is a cell surface associated lipase that displays phospholipase A1 activity towards phosphatidylcholine
present in high-density lipoproteins (HDL). LIPG was recently reported to be expressed in breast cancer and to support
proliferation, tumourigenicity and metastasis. Here we show that severe oxidative stress leading to AMPK activation triggers LIPG
upregulation, resulting in intracellular lipid droplet accumulation in breast cancer cells, which supports survival. Neutralizing
oxidative stress abrogated LIPG upregulation and the concomitant lipid storage. In human breast cancer, high LIPG
expression was observed in a limited subset of tumours and was signiﬁcantly associated with shorter metastasis-free
survival in node-negative, untreated patients. Moreover, expression of PLIN2 and TXNRD1 in these tumours indicated a link
to lipid storage and oxidative stress. Altogether, our ﬁndings reveal a previously unrecognized role for LIPG in enabling
oxidative stress-induced lipid droplet accumulation in tumour cells that protects against oxidative stress, and thus supports
tumour progression.
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What’s new?
Endothelial lipase (LIPG), a cell surface-associated lipase with multifaceted roles, is expressed on breast cancer cells, but its
molecular function and clinical relevance remain unknown. Here the authors uncover a link between oxidative stress and LIPG
upregulation and show that high LIPG expression is associated with shorter metastasis-free survival in women with node-
negative breast cancer. The authors speculate that LIPG may favor metastasis by enabling stress adaptation through lipid
droplet formation and protection of mitochondria.
Introduction
Lipid metabolism is highly relevant in cancer, as supported by
numerous studies describing a role for lipids in cancer-related
cellular processes, such as proliferation and invasion.1,2 The
increased ability of cancer cells to synthesize lipids has led to
the assumption that lipogenesis is the main mechanism by
which cancer cells acquire fatty acids. Indeed, elevated expres-
sion and activity of enzymes involved in lipogenesis, such as
fatty acid synthetase (FASN) are observed in tumour cells and
correlate with cancer progression and worse prognosis in
breast cancer patients.3 However, a recent study uncovered a
pathway of fatty acid supply to cancer cells via lipoprotein
lipase (LPL)-mediated lipolysis of extracellular lipoproteins.4
This showed that not all cancer cells rely exclusively on de
novo fatty acid synthesis (FAS), but can also be fuelled by
exogenous lipids. What determines the relative contribution
of the lipogenic vs. the lipolytic pathways to the intracellular
lipid pool is currently unknown.2 Both pathways may be
coupled to meet the increased demands of highly proliferating
cancer cells for fatty acids as building blocks for more com-
plex lipids. Alternatively, the metabolic fates of fatty acids
derived from exogenous and endogenous sources may be dif-
ferent. The present study provides evidence that oxidative
stress is a key factor shifting the balance towards increased
activity of the lipolytic pathway by upregulating Lipase G,
endothelial type (LIPG).
LIPG was originally identiﬁed in endothelial cells5 as a fur-
ther member of the triglyceride lipase family6 and is a cell
surface-associated lipase with predominantly phospholipase
A1 activity. It cleaves phosphatidylcholine (PC) from high-
density lipoproteins (HDL), thereby releasing free fatty acids
(FFAs) and lysophosphatidylcholine (LPC), which can be
taken up by cells.7 Due to its impact on HDL metabolism,
LIPG has over past decades been primarily studied in the con-
text of cardiovascular disease. Studies on a role for LIPG in
cancer are scarce. We previously reported the upregulation of
LIPG mRNA in a model of oncogene-induced senescence (OIS)
in MCF-7 breast cancer cells, as part of the gene expression
alterations that accompany senescence-associated remodelling
of phospholipids.8 Later, Slebe and coworkers9 reported a broad
and molecular subtype-independent expression of LIPG in
breast cancer and a role for LIPG in providing lipids for
tumour growth. Recently, Lo and coworkers10 described expres-
sion of LIPG in triple-negative breast cancer and a role for
LIPG (independent of its catalytic activity) in promoting metas-
tasis and invasiveness. While the discrepancy in the expression
pattern of LIPG in breast cancer still needs to be clariﬁed, these
reports suggest a multifaceted role of LIPG in tumour progres-
sion that deserves further studies. Remarkably, despite the
essential functions of LIPG discovered in experimental models
no signiﬁcant association of LIPG with survival has been
observed in human breast cancer.9
Our initial ﬁnding that LIPG is upregulated in oncogene-
induced senescence – a state of hypermitotic arrest - prompted
us to hypothesize that LIPG is necessary for survival under
stress conditions, most probably due to its ability to supply cells
with free fatty acids. Here, we report a new and proliferation-
independent role for LIPG in oxidative stress-triggered lipid
droplet accumulation that confers resistance to reactive oxygen
species. Furthermore, in a systematic analysis of own and
publicly available Affymetrix gene expression data we show that
high LIPG mRNA expression is restricted to a small subset of
breast tumours that are predominantly high grade and oestro-
gen receptor (ER)-negative. Finally, we demonstrate that high
LIPG mRNA expression is signiﬁcantly associated with shorter
metastasis-free survival (MFS) in node-negative breast cancer.
Material and Methods
Chemicals
5-Tetradecyl-oxy-2-furoic acid (TOFA), cerulenin, CoCl2, N-ace-
tyl-cysteine (NAC) and lapatinib, were obtained from Sigma
Aldrich. GSK264220A, rotenone, and glutathione (GSH, reduced
ethyl ester) were purchased from Cayman Chemical. The ROS
scavenger MnTMPyP was purchased from Calbiochem/Merck
and diphenyleleiodonium (DPI) from Enzo Biochem.
Cell culture and treatments
The MCF-7 and the SKBR3 breast carcinoma cell lines were
obtained from the American Type Culture Collection (ATCC,
LGC Standards GmbH). MDA-MB-231, MDA-MB-468 and
HCC1954 cells were purchased from the German Collection
of Microorganisms and Cell Cultures (DSMZ). BT747 and
T47D cells were obtained from Cell Lines Service (CLS). The
MCF-7/NeuT cell line was generated and cultivated as
described elsewhere.8,11,12 These cell lines were cultured at 37
C in a humidiﬁed 5% CO2 air atmosphere. MCF-7, MCF-7/
NeuT, MDA-MB-231, MDA-MB-468 and SK-BR-3 cells were
maintained in Dulbecco’s modiﬁed medium (DMEM, 4.5 g/l
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glucose, PAN-Biotech), supplemented with 10% foetal bovine
serum (FBS, PAN-Biotech). For the MCF-7/NeuT cell line
tetracyclin-free FBS (PAN-Biotech) was used. BT-474 and
T-47D cells were maintained in DMEM:F12, 10% FCS and
1% L-Glutamine (all from PAN-Biotech) and HCC1954
cells were cultivated in RPMI1640 with 10% FCS and 1%
Sodium Pyruvate (Gibco). The HER2 wildtype and HER2
insYVMA MCF7 cell lines were established by retroviral
transduction of MCF-7 cells with the corresponding plasmids13
and cultivated in RPMI with 10% FCS, 1% Pen/Strep and 1%
L-Glutamine in the presence of puromycin (0.250 μg/mL). Cell
exposure to hypoxia (1% O2) was performed in a modular
hypoxia/hyperoxia CO2 incubator (CB53, Binder). The cell cul-
ture media was pre-equilibrated in the hypoxia incubator over
night. Expression of LIPG and ACACA (the gene coding for
the catalytic subunit alpha of Acetyl-CoA Carboxylase) was
transiently downregulated using siRNA as described in Supple-
mental Material.
All cell lines were regularly tested for mycoplasma (Venor
GeM Classic Mycoplasma Detection kit, Minerva Biolabs),
and authenticated (DSMZ).
LIPG overexpression
MCF7 cells were transiently transfected with the full-length
human LIPG cDNA cloned into pCMV/hygro–FLAG vector or
with the empty vector (Sino Biological Inc.). Transfections
were performed with the X-tremeGENE HP DNA transfection
reagent according to the manufacturer’s instructions (Sigma
Aldrich) for 48 h. When applicable, 48 h after transfection cells
were fed with either 800 μg high density lipoprotein (HDL,
BioTrend) or 800 μg phospholipid (1,2-dioleoyl-sn-glycero-
3-phosphocholine DOPC (PC-OA) (Avanti Polar Lipids) for a
further 48 h. HDL was purchased ‘ready to use’. Preparation of
phospholipid vesicles and oleic acid/bovine serum albumin
(OA/BSA) complex is described in Supplemental Material.
Immunoblotting
Standard immunoblot analysis was performed as described
elsewhere.11 Antibodies were diluted in 5% BSA/Tris-buffered
saline Tween-20. Details about source, dilution and incubation
conditions are provided in Supplemental Material. Protein signals
were detected by enhanced chemiluminiscence (PerkinElmer
LAS). Quantiﬁcation of Western blots was done with ImageJ.
The density of the protein of interest was always adjusted to the
density of the corresponding loading control.
Triacylglyceride quantiﬁcation
Triglyceride levels in cells were quantiﬁed using the commer-
cially available Triglyceride Quantiﬁcation Kit (Abcam),
according to the manufacturer’s instructions. The ﬂuores-
cence (Ex/Em 535/587 nm) was measured using a Tecan
Inﬁnite 200PRO plate reader (Tecan Group AG). The pro-
tein concentration of the extract was quantiﬁed using the
Pierce BCA Protein Assay Kit (Thermo Fisher Scientiﬁc),
according to the manufacturer’s instructions, and used to
normalize the ﬂuorescent signal.
Quantiﬁcation of mitochondrial membrane potential
Cells were incubated with tetramethylrhodamine methylester
perchlorate (TMRE) (Invitrogen), for 20 min at 37 C at a ﬁnal
concentration of 10 μM in medium containing serum. After
washing with PBS, cells were trypsinized and the ﬂuorescence
of loaded TMRE (Ex/Em 545/575) was quantiﬁed in a plate
reader (Tecan SpectraFluor Plus). For normalization, cell number
was determined with a CASY cell counter (Innovatis AG/Roche).
Quantiﬁcation of reactive oxygen species with the TBARS
assay
Quantiﬁcation of malondialdehyde (MDA) in cells (2x107 cells
collected in 1 mL PBS) was performed with the TBARS assay
(Cayman Chemical) according to the colorimeric version of the
manufacturer’s instructions. Absorbance was read at 530–540 nm
with a plate reader (Tecan SpectraFluor Plus).
Viability assay
Determination of the number of viable cells after treatments
in multiwell plates was performed with the CellTiter-Blue®
Cell Viability Assay (Promega) according to manufacturer’s
instructions. MCF-7 cells were incubated with the redox dye
resazurin for 4 h. The ﬂuorescent end product was measured
in a Greiner 96 Flat Bottom Black Polystyrol 96-well plate
(Ex/Em 540/590 nm) using a Tecan Inﬁnite 200PRO plate
reader (Tecan Group AG).
Immunoﬂuorescence analysis
Cells were seeded on coverslips and, after the indicated treat-
ments, a standard immunoﬂuorescence protocol was performed.
Details about source, dilution of the antibodies used and incuba-
tion conditions are provided in Supplemental Material. Cover-
slips were mounted and examined under a confocal laser
scanning microscope (Olympus CLSM FV1000).
For visualization of lipid droplets, cells were stained after
ﬁxation and permeabilisation with either Oil Red O (Sigma
Aldrich) for 30 min14 or with BODIPY® 493/503 (Life tech-
nologies) for 45 min. For visualization of actin ﬁlaments, cells
were stained with rhodamine-labeled phalloidin (Invitrogen)
for 45 min at room temperature.
Quantitative PCR
Total RNA extraction was performed with either the RNeasy
Mini Kit (Qiagen) or the innuPREP RNA kit (Analytic Jena),
according to the standard protocol of the manufacturer.
RNA (2 μg) was transcribed to cDNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems). Real-time quantitative PCR was performed with the
Applied Biosystems ABI 7500 Fast Real-Time PCR System
using the TaqMan technique. UBC was used as the reference
gene for normalization. Taqman expression assays are found
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under Supplemental Material. Relative gene expression was
calculated according to the 2-ΔΔCt method.15
Heparin-release
For detection of the secreted, cell surface-bound fraction of
LIPG, cells were washed with PBS and incubated in serum-
free medium containing 10–25 U/mL heparin (Sigma Aldrich)
for 16 h at 37 C. The cell supernatants were collected in ice-
cold tubes and after removal of dead cells by centrifugation,
protein was precipitated using a standard ammonium sulfate
precipitation procedure. Protein pellets were analysed by
immunoblotting. Because no loading control was available for
the immunoblotting of the supernatants, the signal intensity
calculated with ImageJ was normalized to the total amount of
protein of the corresponding cell cultures.
Immunohistochemistry of breast cancer tissue
Formalin-ﬁxed parafﬁn-embedded (FFPE) tissue blocks
from 258 node-negative, systemically untreated, breast
cancer patients (See Table S1, Supporting Information
with clinicopathological characteristics), who were oper-
ated between 1988 and 2000 at the Department of Obstet-
rics and Gynecology, Johannes Gutenberg University,
Mainz, were used to construct a tissue microarray (TMA).
The study was approved by the Research Ethics Commit-
tee of the University Medical Centre Mainz, Germany, and
informed consent was obtained from all patients. Descrip-
tion of TMA construction and staining procedure is found
in Supplemental Material. The stained TMA slides were
scanned using a Hamamatsu NanoZoomer 2.0 whole slide
scanner. LIPG cytoplasmic positivity was assessed by man-
ual annotation of the scanned images at 10-40x magniﬁca-
tion, based on the staining intensity which was categorized
as (0) negative/weak, (1) moderate, and (2) strong. One
score was obtained from the duplicate tissue cores repre-
senting each tumour.
Transcriptomics datasets
LIPG (probeset 219181_at), PLIN2 (209122_at) and TXNRD1
(201266_at) expression in human breast cancer were analysed
in Affymetrix GeneChip HG U133 A or Plus 2.0 gene expres-
sion microarray datasets that were accessed from the Gene
Expression Omnibus (GEO) web portal (https://www.ncbi.
nlm.nih.gov/geo/).16 Duplicated patients were excluded. Clinico-
pathological characteristics and literature references for the analysed
cohorts are summarized in Table S2, Supporting Informa-
tion. Frozen robust multiarray analysis (fRMA)17 was used
for the normalization of the Affymetrix data.
For additional analysis of LIPG expression, RNA-seq data
from the Cancer Genome Atlas (TCGA) breast cancer dataset
(BRCA) was used, including 1,125 tumour and 97 matched
healthy tissue samples, accessed from the Genomic Data Com-
mons (GDC) web portal (https://gdc-portal.nci.nih.gov/), as
described.18 The TCGA BRCA dataset included 180 stage I,
609 stage II, 243 stage III, and 20 stage IV tumours (for 11 tumours,
no information about stage was available).
Statistical analysis
All analyses of transcriptomics data were performed using R
version 3.2.1 (R core team, 2015, http://www.r-project.org/).
Categorization of clinical variables age, grade, pT stage, ER
and HER2 status, dichotomization of LIPG expression, calcu-
lation of univariate and multivariate Cox analysis and likeli-
hood ratio statistic are described in detail in Supplementary
Material. Analyses of cell culture results were performed using
GraphPad Prism, version 6 (La Jolla, CA, USA).
Results
LIPG enables cancer cells to use circulating lipoproteins as
a nutrient source and promotes lipid storage
Previous work has shown that LIPG exerts phospholipase A1
activity towards high-density lipoprotein (HDL)-derived phos-
phatidylcholine (PC),19 releasing lipid products that become
incorporated into intracellular PC and triacylglyceride (TAG)
pools.7 Therefore, we investigated whether this also applies to
breast cancer cells. First, endogenous expression of LIPG
mRNA was measured in breast cancer cell lines of different
subtypes: MCF-7 and T47D (ER+/HER2-), BT474 (ER
+/HER2+), MDA-MB231 and MDA-MB-468 (ER-/HER2-)
and SKBR3 and HCC1954 (ER-/HER2+). The results
revealed the lowest LIPG mRNA levels in MCF-7 and the
highest in MDA-MB-468 and HCC1954 cells (Fig. S1a, Sup-
porting Information). This expression pattern was supported
by Western blot analysis of the cell culture supernatants, but
was not observed in cell lysates (Fig. S1b, Supporting Infor-
mation), indicating that LIPG transcription is followed by
secretion of the mature 68 kDa LIPG protein.
LIPG was overexpressed in MCF-7 cells using a vector
containing LIPG tagged at the C-terminus with a FLAG epi-
tope and overexpression was conﬁrmed by qPCR, immuno-
blotting and immunoﬂuorescence (Figs. S2a-S2c, Supporting
Information). LIPG overexpression (LIPG-OE) in the presence
of HDL resulted in an increase in intracellular TAG levels, as
well as in the upregulation of the lipid droplet (LD)-coating
protein Perilipin 2 (PLIN2), and LD accumulation (Fig. 1a)
compared to cells transfected with vector alone (EV) and to
non-transfected cells (FM control, Fig. S2d, Supporting Infor-
mation). Besides HDL, also pure PC vesicles (PC esteriﬁed
with oleic acid (PC-OA) served as a LIPG substrate, resulting
in elevated levels of TAG, increased accumulation of LD, and
upregulation of PLIN2 expression (Fig. 1b). Addition of OA,
one of the most abundant fatty acids released by LIPG,20 to
both LIPG-OE and EV-transfected cells resulted in compara-
ble increases in TAG accumulation, PLIN2 upregulation and
LD accumulation irrespective of LIPG expression (Fig.1c) as
also shown in OA-treated parental MCF-7 cells (Fig. S2e, Sup-
porting Information). LIPG overexpression in absence of sub-
strate (Fig. 1d) did not elicit such a response, suggesting that
4 LIPG in breast cancer
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both LIPG and substrate are required to increase the intracel-
lular TAG pool. These results demonstrate that MCF-7 breast
cancer cells are able to incorporate exogenous free fatty acids
into TAGs, but only LIPG expression renders them capable of
using HDL or PC as a fatty acid source.
Given that LIPG overexpression results in intracellular lipid
storage in MCF-7 cells, we investigated whether upregulation of
endogenous LIPG by sustained oncogenic signalling in MCF-7/
NeuT cells was also associated with elevated intracellular TAG.
Previously, we observed upregulation of LIPG mRNA in MCF-
7/NeuT breast cancer cells which conditionally overexpress an
oncogenic variant of the rat Her2/Erbb2/Neu receptor tyrosine
kinase (NeuT), leading to oncogene-induced senescence (OIS).8
After demonstrating doxycycline (dox)-triggered expression of
NeuT, together with the EGFP reporter and the characteristic
morphological changes associated with premature senescence,
such as cell enlargement and ﬂattening (Figs. 2a and 2b), we
conﬁrmed a more than tenfold upregulation of LIPG mRNA by
qPCR (Fig. 2c and Fig. S3a, Supporting Information). LIPG pro-
tein was detected in the supernatant of the senescent MCF-7/
NeuT (+dox), but not in control (−dox) cells, as the 68 kDa full-
length glycosylated form together with its 40 kDa cleavage prod-
uct (Fig. 2d and Fig. S3b, Supporting Information). This demon-
strates that induction of LIPG transcription is followed by
secretion of LIPG protein. Cytoplasmic LIPG protein levels were
not increased by dox treatment (Figs. S3c-S3d, Supporting Infor-
mation). Thus, the inducible 68 kDa LIPG protein pool becomes
readily secreted and is only detected in the extracellular fraction.
No other members of the triglyceride lipase family were shown to
be signiﬁcantly up or downregulated upon NeuT induction in
MCF7/NeuT cells (Table S3, Supporting Information).
MCF-7/NeuT cells examined 6d after NeuT induction
(6d + dox) showed a threefold increase in TAG levels com-
pared to control cells (6d-dox) (Fig. 2e). Consistently, PLIN2
was also upregulated in MCF-7/NeuT cells upon NeuT induc-
tion (Fig. 2f ). Blockage of LIPG activity with the LIPG inhibitor
GSK264220A21 signiﬁcantly reduced intracellular TAG levels
(Fig. 2g) and LD accumulation (Fig. 2h) in MCF-7/NeuT cells.
Thus, the increased triglyceride levels observed in NeuT-
induced senescence depend partially on LIPG activity.
LIPG expression is upregulated in oxidative stress
conditions that compromise de novo fatty acid synthesis
Subsequent analyses aimed to identify stimuli that are able
to upregulate LIPG. Upregulation of LIPG in MCF-7/NeuT
cells after induction of oncogenic HER2 (NeuT) suggested
that LIPG could be a target of HER2. However, upregulation
of LIPG by HER2 has not been reported in other studies.
Therefore, we investigated LIPG expression in MCF-7 cells
stably transfected with wildtype HER2 or with a HER2
mutant containing a YVMA insertion in the kinase domain
(A775_G776) that also enhances tyrosine kinase activity13,22
and activates AKT, MEK1/2-ERK1/2 and P38 signalling
pathways as described for NeuT11,12 (Fig. S4a, Supporting
Information). qPCR analysis did not show an upregulation
of LIPG in the HER2 insYVMA or the HER2 wildtype over-
expressing MCF-7 cells (Fig. S4b, Supporting Information).
This suggests that LIPG expression is not generally triggered
by HER2. Rather, LIPG expression in MCF-7/NeuT cells
may be the consequence of a metabolic reprogramming
induced by the hyperactive NeuT.
One further hypothesis was that a compromised de novo
lipogenesis may induce pathways of exogenous lipid uptake in
breast cancer cells. Therefore, we pharmacologically inhibited
de novo FAS in MCF-7 cells by the acetyl CoA carboxylase
(ACC) inhibitor 5-tetradecyl-oxy-2-furoic acid (TOFA)23 and
by the FASN inhibitor cerulenin (Fig. 3a). Inhibition by
TOFA but not by cerulenin resulted in a signiﬁcant upregula-
tion of LIPG mRNA (Fig. 3b) in a concentration-dependent
manner (Fig. S5a, Supporting Information). This suggests that
impairing ACC activity may determine LIPG upregulation.
Silencing of the ACC catalytic subunit ACACA via transfec-
tion with siRNA (Fig. S5b, Supporting Information) also
resulted in a slight upregulation of LIPG mRNA (Fig. S5c,
Supporting Information) and supported the hypothesis that
LIPG compensates a diminished de novo FAS.
Accordingly, we next studied whether ACC is inhibited in
senescent MCF-7/NeuT cells. Different stress conditions, includ-
ing reactive oxygen species (ROS), activate the AMP-kinase
(AMPK), which in turn phosphorylates and inhibits ACC
(Fig. 3a).24,25 An increase in ROS generation has been demon-
strated in MCF-7/NeuT and other models of oncogene-induced
senescence (OIS),11,26 including lipid peroxides11 as well as super-
oxide anions and hydrogen peroxide.26 Thus, as expected, we
conﬁrmed the previously observed upregulation of thioredoxin
reductase (TXNRD1)11 (Fig. 3c) and increased levels of thiobarbi-
turic acid reactive substances (TBARS) (Fig. 3d) as measures of
ROS-mediated lipid peroxidation and demonstrated phosphoryla-
tion (activation) of AMPK (Fig. 3e) and phosphorylation (inhibi-
tion) of ACC (Fig. 3f) in senescent MCF-7/NeuT cells. Together,
these data suggest that oxidative stress is a biological context in
which fatty acid synthesis is inhibited, and the resulting compen-
satory induction of LIPG occurs.
LIPG protects from mitochondrial dysfunction under
metabolic stress conditions
Published studies have shown that fatty acids derived from
intracellular LD-lipolysis support cells during starvation,27
and are delivered to mitochondria.28 This is supported by the
association of PLIN2-positive LDs with mitochondria.28,29 We
conﬁrmed the relevance of LDs in cell survival by monitoring
cell growth during the course of a feeding-starvation experi-
ment. As shown in Figure S6a, Supporting Information, cells
fed with OA had a survival advantage during starvation. To
study a possible contribution of LDs in mitochondrial integ-
rity, tetramethylrhodamine methyl ester perchlorate (TMRE),
which only accumulates in functional mitochondria with
transmembrane potential (Δψm), was monitored. TMRE
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levels were higher in cells that had lipid stores available during
starvation (Fig. S6b, Supporting Information).
We next investigated whether LIPG-mediated lipid supply
confers a survival advantage to cells. To this end we explored
whether LIPG-mediated LD accumulation supports mitochon-
dria under conditions of compromised FAS. When blocking de
novo FAS with TOFA in LIPG-OE and EV transfected cells fed
with PC-OA, mitochondrial integrity was higher in LIPG overex-
pressing cells than in control cells (Fig. 3g), supporting that LIPG
provides a survival advantage once endogenous FAS is limited.
Upregulation of LIPG by CoCl2 contributes to lipid storage
and adaptation to oxidative stress and is abrogated by ROS
scavengers
To investigate further oxidative stress stimuli, we used the
hypoxia-mimicking and ROS-inducing agent cobalt chloride
(CoCl2). Exposure of MCF-7 cells to CoCl2 resulted in AMPK
phosphorylation in a concentration-dependent manner (Fig. 4a).
Although phosphorylation of the AMPK-target ACC was not
increased, total ACC protein levels decreased signiﬁcantly
(Fig. 4b) in agreement with studies showing that AMPK can also
regulate ACC at the transcriptional level, repressing its promoter
activity via NRF-1.30 LIPG was upregulated more than ﬁvefold at
high concentrations of CoCl2 (0.9 mM) (Fig. 4c). In line with the
ROS-generating effect of CoCl2, which has been reported to
increase superoxide production by mitochondria,31 TXNRD1
mRNA was also induced (Fig. 4c). CoCl2 also led to the upregu-
lation of PLIN2 mRNA (Fig. 4c) and to increased levels of TAG
and LDs (Fig. 4d). The contribution of LIPG to CoCl2-triggered
lipid storage was demonstrated by showing restoration of basal
TAG levels and concomitant reduction of the amount of LDs
(Figs. 4e and 4f) upon inhibition of LIPG with GSK264220A.
Figure 1. LIPG overexpression in MCF-7 cells results in intracellular lipid storage. MCF-7 cells were transfected with a LIPG construct (LIPG-OE)
or an empty vector (EV) and incubated for 48 h with (a) 800 μg HDL, (b) 800 μg PC-OA in serum-free DMEM, (c) 800 μg oleic acid
(OA) complexed to bovine serum albumin and (d) no substrate. Intracellular triacylglyceride (TAG) levels were quantiﬁed with the triglyceride
quantiﬁcation assay kit. PLIN2 mRNA levels were analysed by qPCR. Lipid droplets were visualized with Bodipy 493/503 staining (green).
Nuclei were stained with DAPI (blue). The bars represent the mean SEM and pictures are representative of three independent experiments.
*p < 0.05; **p < 0.01; ***p < 0.001, unpaired two-tailed Student’s t-test. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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Furthermore, also knockdown of LIPG, which showed >80%
reduction of LIPG mRNA and loss of the secreted 68 kDa LIPG
protein led to a decreased cellular TAG content (Figs. S7a-S7d,
Supporting Information). Moreover, it prevented upregulation of
LIPG upon exposure to CoCl2 (Fig. 4g) and led to a signiﬁcant
decrease in cell viability (Fig. 4h), demonstrating a role for LIPG
in adaptation to oxidative stress.
Because CoCl2 also acts as a hypoxia mimetic, we
explored the possible upregulation of LIPG by hypoxia. We
observed no hypoxia-speciﬁc upregulation of LIPG (Fig. S8,
Supporting Information), rather a cell density-dependent
downregulation. A similar pattern was shown for TXNRD1.
Hypoxia-dependent upregulation of PLIN2 accompanied
the increased expression of the hypoxia marker VEGF
(Fig. S8, Supporting Information), which altogether sug-
gests a hypoxia-triggered LD accumulation in a LIPG-
independent manner. Incubation of cells with H2O2 also led
to a slight but signiﬁcant induction of LIPG and TXNRD1
Figure 2. Upregulation of LIPG in NeuT-induced senescence contributes to lipid storage. (a) Representative Western blot showing expression of
the NeuT oncogene in MCF-7/NeuT cells treated with doxycycline (+dox) or untreated (−dox) at different time points. (b) Immunoﬂuorescence
illustrating senescence-associated morphological changes and co-induction of the reporter EGFP (green) upon dox treatment. The actin
cytoskeleton was stained with rhodamine phalloidin (red); nuclei were stained with DAPI (blue); scale bar: 50 μm. (c) qPCR showing LIPG mRNA
expression in MCF-7/NeuT cells incubated with/without dox during the indicated time periods. Data represent the mean fold change in mRNA
relative to time point 0 h  SEM (n = 3). (d) Representative Western blot showing the 68 kDa LIPG protein and its 40 kDa cleavage product in
supernatants of MCF-7/NeuT cells (6d −/+ dox) incubated with heparin and densitometric quantiﬁcation of the 68 kDa LIPG band from Western
blots signals of three independent experiments (see also Fig. S3, Supporting Information). (e) Quantiﬁcation of cellular triacylglycerides (TAG) in
MCF-7/NeuT cells cultivated for 7d with/without dox (time point of high LIPG expression). (f ) PLIN2 mRNA expression, analysed by qPCR as in
(c). (g) Quantiﬁcation of cellular triacylglycerides (TAG) in MCF-7/NeuT cells cultivated for 6d with/without dox (dox) in the presence or
absence of 16 nM or 32 nM of the LIPG inhibitor GSK264220A. (h) Oil Red O (ORO) staining (red) to visualize lipid droplets in MCF-7/NeuT cells
treated for 6d-7d dox in the presence or absence of the LIPG inhibitor GSK264220A (32 nM); blue: DAPI green: EGFP. Scale bar: 40 μm. All bar
plots represent the mean  SEM of three independent experiments. **p < 0.01; ***p < 0.001 (for comparison between –dox and + dox
incubated cells); #p < 0.05 (dox + GSK264220A-incubated vs. dox only-incubated cells); +p < 0.05 (GSK264220A-treated vs. untreated cells).
p-Values were calculated by unpaired two-tailed Student’s t-test. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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Figure 3. LIPG becomes upregulated upon cellular stress-mediated inhibition of de novo fatty acid synthesis (FAS). (a) Schematic illustration
of the initial steps of de novo FAS, regulation of acetyl-CoA carboxylase (ACC) by AMPK, and pharmacological inhibition by TOFA and
cerulenin. (b) qPCR analysis of LIPG mRNA expression in MCF-7 cells incubated for 24 h with 6 μM TOFA (n = 4). (c) Representative Western
blot showing protein levels of TXNRD1 in MCF-7/NeuT cells incubated with/without dox at the indicated time points. (d) TBARS assay showing
levels of ROS in cellular extracts of MCF-7/NeuT cells incubated 7d with/without dox (n = 3). (e) Representative Western blots showing the
phosphorylation status of AMPK in MCF-7/NeuT cells (6d with/without dox) and densitometric quantiﬁcation of the ratios of phospho-AMPK
(p-AMPK) and total-AMPK (t-AMPK) to β-actin from Western blot signals of three independent experiments. (f ) Representative Western blot
showing the phosphorylation status of ACC in MCF-7/NeuT cells (6d with/without dox) and densitometric quantiﬁcation of the ratios of
phospho-ACC (p-ACC) and total-ACC (t-ACC) to calnexin from Western blot signals of three independent experiments. Bars indicate mean 
SEM. ***p < 0.001; *p < 0.05, unpaired two-tailed Student’s t-test. (g) Mitochondrial integrity of cells transfected with LIPG or empty vector
(EV), fed with LIPG substrate (PC) and subsequently treated with TOFA to block fatty acid synthesis. The bar diagrams represent the mean 
SEM of three independent experiments. ***p < 0.001, unpaired two-tailed Student’s t-test.
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(Fig. S9a, Supporting Information), and treatment with rote-
none, which results in superoxide generation, led to an even
higher upregulation of LIPG and TXNRD1 (Fig. S9b, Support-
ing Information), again reinforcing the link between LIPG and
oxidative stress.
Altogether, these results strongly support the concept that
oxidative stress upregulates LIPG as an alternative lipid supply
pathway in breast cancer cells where de novo FAS is compro-
mised by ROS.
In view of these results, we tested the ability of the ROS
scavenger N-acetyl-cysteine (NAC) to counteract the effects of
CoCl2. Addition of NAC abrogated CoCl2-triggered phos-
phorylation of AMPK (Fig. 4i). Furthermore, both LIPG and
PLIN2 induction were prevented in the presence of NAC
(Fig. 4j). TXNRD1 expression also decreased to control levels,
conﬁrming efﬁcient scavenging of ROS (Fig. 4j). Moreover,
TAG levels were normalized upon NAC treatment (Fig. 4k)
and no accumulation of LDs was observed (Fig. 4l). Supple-
menting CoCl2-treated MCF-7 cells with GSH partially pre-
vented LIPG and TXNRD1 upregulation as well (Fig. S10,
Supporting Information). Hence, counteracting oxidative
stress prevents the upregulation of LIPG as well as LIPG-
mediated lipid storage.
In senescent MCF-7/NeuT cells neither NAC nor the super-
oxide scavenger Mn(111) tetrakis 1-methyl 4-pyridyl porphyrin
pentachloride (MnTMPyP) nor diphenyleneiodonium chloride
(DPI), an inhibitor of NADPH oxidase-like ﬂavoenzymes,
which efﬁciently scavenged ROS in other models of OIS,32,33
counteracted oxidative stress (Figs. S11a-S11c, Supporting
Information). Accordingly, LIPG and TXNRD1 levels remained
high (Figs. S11a-S11c, Supporting Information). Only the inhi-
bition of the tyrosine kinase activity of HER2/NeuT with lapati-
nib markedly decreased LIPG levels and slightly diminished
TXNRD1 mRNA. (Fig. S11d, Supporting Information). Thus,
oxidative stress caused by the constitutively active NeuT in
MCF-7/NeuT cells cannot be efﬁciently scavenged by conven-
tional antioxidants. Only by antagonizing its tyrosine kinase
activity was LIPG upregulation inhibited. A striking observation
was the strong upregulation of LIPG, PLIN2, and TXNRD1 in
control cells (−dox, non-senescent) upon treatment with DPI
and MnTMPyp. This suggests that LIPG upregulation also
occurs in response to reductive stress, and is thus responsive to
general disturbances in the cellular redox state.
High LIPG expression associated with shorter metastasis-
free survival in human node-negative breast cancer
Recent reports indicate the relevance of LIPG in human breast
cancer.9,10 However, discrepancies between the studies with
regard to LIPG expression remained unclariﬁed. We analysed
LIPG gene and protein expression in our previously established
breast cancer cohort (Mainz cohort, GSE11121) of node-negative
breast cancer patients who were untreated in both neoadjuvant
and adjuvant settings.34,35 LIPG mRNA (Affymetrix probeset
219181_at) revealed a bimodal expression distribution, where a
small subset of tumours expressed high LIPG levels (Fig. 5a and
Fig. S12a, Supporting Information). To validate this ﬁnding, we
explored additional, publicly available breast cancer cohorts. A
similar distribution, with only a relatively small subset of
tumours expressing high levels of LIPG, was also observed in
three publicly available node-negative, untreated breast cancer
cohorts, as well as in several datasets of patients who received
adjuvant or neoadjuvant therapy (Fig. 5a and Figs. S12a-S12c,
Supporting Information). Comparing LIPG levels analysed by
Affymetrix gene array and qPCR for a selection of tumours
from the Mainz cohort, for which RNA was available, revealed
a strong correlation between the two methods (Pearson
r = 0.96, p < 0.001) (Fig. 5b) and excluded that the observed
expression pattern was due to probeset-dependent effects.
Moreover, also in the TCGA breast cancer dataset, including
data from 1,125 specimens analysed with RNA sequencing
(https://tcga-data.nci.nih.gov/) was only a small subset of breast
tumours with high LIPG expression observed (Fig. S13a, Sup-
porting Information), further indicating that high LIPG expres-
sion is rare in human breast cancer.
In the Mainz cohort, higher LIPG expression was signiﬁcantly
associated with shorter MFS in a univariate Cox analysis
(Table S4, Supporting Information). The small subset of patients
with tumours expressing high LIPG levels showed signiﬁcantly
shorter MFS, illustrated by a Kaplan–Meier plot (Fig. 5c, left
panel). In contrast, a recent study9 investigating LIPG protein
levels in a TMA of 439 breast cancer patients using immunohis-
tochemistry (IHC), reported high and ubiquitous expression of
LIPG, and no association with outcome. Interestingly, when a
TMA including the patients of the Mainz cohort was immunos-
tained using the same antibody as Slebe et al.,29 broad cytoplas-
mic LIPG expression was also observed (Fig. 5d, upper and
lower left panel), and there was no association of LIPG positivity
with clinicopathological parameters (Table S5, Supporting Infor-
mation) or MFS (Fig. 5d, lower middle panel). Importantly, we
observed no correlation between cytoplasmic LIPG protein stain-
ing by IHC with this antibody and mRNA levels (Fig. 5d, lower
right panel). This is in line with the results obtained in vitro,
showing that not cytoplasmic but secreted LIPG reﬂects mRNA
levels.
To further validate the association of high LIPG mRNA
expression with MFS, three additional node-negative, untreated
breast cancer datasets (GSE2034 n = 286; Transbig: GSE6532
n = 84 and GSE7390 n = 196; and GSE5327 n = 58) were ana-
lysed. As observed in the Mainz cohort, a signiﬁcantly shorter
MFS was observed for high LIPG-expressing tumours in the
Transbig cohort (Table S4, Supporting Information), as well as in
the combined node-negative dataset (Table 1), illustrated by
Kaplan–Meier plots (Fig. 5c, right panel). In the combined node-
negative dataset, high LIPG expression correlated with ER nega-
tive status (p < 0.001) and high tumour grade (P = 0.014)
(Table S6, Supporting Information). Interestingly, in a multivari-
ate Cox analysis, LIPG was associated with worse prognosis, inde-
pendent of grade, stage, age, ER-, and HER2 status (Table 1).
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Figure 4. Upregulation of LIPG by CoCl2 contributes to lipid storage and adaptation to oxidative stress and is abrogated by ROS
scavengers. (a) Representative Western blot showing AMPK phosphorylation in MCF-7 cells exposed to different concentrations of CoCl2 for
24 h and densitometric quantiﬁcation of the ratio (phospho-AMPK/total-AMPK) from Western blot signals of three independent
experiments. (b) Representative Western blot showing ACC phosphorylation in MCF-7 cells exposed to 0.89 mM of CoCl2 for 24 h and
densitometric quantiﬁcation of the ratios (p-ACC and t-ACC to calnexin) from Western blot signals of three independent experiments. (c)
qPCR analysis showing LIPG, PLIN2 and TXNRD1 mRNA levels in MCF-7 cells treated for 24 h with the indicated concentrations of CoCl2. (d)
Quantiﬁcation of triacylglycerides (TAG) in MCF-7 cells exposed for 24 h to the indicated concentrations of CoCl2 and visualization of lipid
droplets by BODIPY 493/503 staining (green) in 0.89 mM CoCl2-treated and untreated (FM) MCF-7 cells; red: Rhodamine phalloidin
staining of the actin cytoskeleton; blue: DAPI. Scale bars: 20 μm. (e) Visualization of lipid droplets in MCF-7 cells exposed to 0.89 mM
CoCl2 for 24 h in the presence or absence of 16 nM or 32 nM of the LIPG inhibitor GSK264220A. red: Rhodamine phalloidin staining of
the actin cytoskeleton; blue: DAPI. Scale bars: 40 μm. (f ) Quantiﬁcation of TAGs in CoCl2-treated MCF-7 cells in the presence or absence of
16 nM or 32 nM GSK264220A (duplicates are shown). (g) qPCR analysis showing LIPG mRNA levels in MCF-7 cells after transfection with
scrambled si-RNA as a negative control (si-neg) and two different si-RNA oligos targeting LIPG (si-LIPG-A and si-LIPG-B), compared to FM
(full media, non-transfected control) and Lipo (Lipofectamine only, mock-transfected) and subsequent 24 h-exposure to CoCl2. (h) Cell Titer
Blue viability assay showing cell survival after three more days under the same conditions as in (g). Bar diagrams represent the mean 
SEM of three independent experiments; *p < 0.05; **p < 0.01; ****p < 0.0001 for comparison of each of the siRNAs with the negative
control (scramble, si-neg). ####p < 0.0001; ###p < 0.001 for comparisons to untreated cells (FM). p-Values were calculated by unpaired two-
tailed Student’s t-test. (i) Representative Western blot showing AMPK phosphorylation in MCF-7 cells exposed to 0.5 mM or 0.89 mM CoCl2
alone or in the presence of 20 mM NAC for 24 h and densitometric quantiﬁcation of the ratio (phospho-AMPK/total-AMPK) from Western
blot signals of three independent experiments. ( j) qPCR analysis showing mRNA levels of LIPG, PLIN2 and TXNRD1 in MCF-7 cells exposed
to CoCl2 in the presence or absence of 20 mM NAC. (k) Quantiﬁcation of cellular TAGs in MCF-7 cells exposed to CoCl2 in the presence or
absence of NAC. (l) Visualization of lipid droplets by BODIPY 493/503 (green) in CoCl2-treated in MCF-7 cells in the presence or absence
of 20 mM NAC; red: Rhodamine phalloidin staining of the actin cytoskeleton; blue: DAPI Scale bars: 40 μm. All bar diagrams represent the
mean  SEM of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 (CoCl2-treated vs. untreated cells); #p < 0.05;
##p < 0.01; ###p < 0.001 (NAC-treated or GSK264220A-treated vs. untreated cells). p-Values were calculated by unpaired two-tailed
Student’s t-test. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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Next, analysing the association of LIPG with MFS in more
heterogeneous patient populations, including also node-
positive patients and patients who received adjuvant treatment
with hormonal drugs and/or chemotherapy revealed a signiﬁ-
cant association of high LIPG expression with worse outcome
in one dataset, but was not conﬁrmed to be a general feature
of human breast cancer (Figs. S12 and S13, Supporting Infor-
mation). The lack of association with MFS in tamoxifen-
treated breast cancers is however not surprising, since it is in
line with our ﬁndings that LIPG was associated with ER-
negative status (Table S6, Supporting Information). That no
signiﬁcant association was observed between high LIPG expres-
sion and MFS in the datasets where all, or the majority of
patients were treated with adjuvant chemotherapy might be
due to factors related to the chemotherapy response being more
important for metastatic recurrence in an adjuvantly treated
patient population.
The previously described in vitro experiments demonstrated
that LIPG supports lipid droplet formation and mitochondrial
integrity under conditions of oxidative stress. These ﬁndings
were supported in the combined node-negative dataset where the
majority of LIPG-high tumours also expressed the lipid droplet
marker PLIN2, and the oxidative stress marker TXNRD1 at levels
above the median (Figs. 5e and 5f). Both PLIN2 (209122_at) and
TXNRD1 (201266_at) were also signiﬁcantly associated with
shorter MFS in the combined node-negative dataset in a univari-
ate Cox analysis (Tables S7 and S8, Supporting Information), as
illustrated by Kaplan–Meier plots (Fig. S14a, Supporting Informa-
tion) and in previous work.11 However, for the combined node-
negative dataset, adding LIPG to the model that included PLIN2
or TXNRD1 corresponded to a signiﬁcant increase in the likeli-
hood ratio statistic (Fig. S14b, Supporting Information). This
shows that including LIPG as a variable adds a signiﬁcant
amount of prognostic information to the model, in addition to
PLIN2 or TXNRD1, and is not simply a marker of lipid accumu-
lation. As illustrated by Kaplan–Meier plots, survival was worse
when both PLIN2 and LIPG expression were high (Fig. 5g), with
similar results being obtained for LIPG and TXNRD1 (Fig. 5h).
In summary, high LIPG mRNA expression occurred in a small
subset of breast tumours, primarily high grade and ER-negative,
Figure 4. Continued
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and was associated with shorter MFS in node-negative, systemi-
cally untreated tumours. Co-expression of LIPG mRNA with
TXNRD1, and PLIN2 suggests a role for LIPG in the context of
oxidative stress and lipid droplet accumulation, while simulta-
neously supporting the results obtained in vitro.
Discussion
The present study has uncovered two new aspects of the role
of LIPG in breast cancer: First, high LIPG expression, which
provides an alternative source of FFA to de novo synthesis via
extracellular lipolysis, is particularly relevant under oxidative
Figure 5. Expression of LIPG in human breast cancer and association with metastasis-free survival. (a) Box plots showing the distribution
of LIPG mRNA expression in 18 breast cancer datasets, including node-negative, untreated cohorts as well as cohorts of patients who
had received adjuvant (tamoxifen (TAM) only), hormonal and/or chemotherapy and/or both and/or unknown treatment (adjuvant*) and
neoadjuvant therapy. (b) Correlation of Affymetrix and qPCR results with Pearson correlation r = 0.9623, p < 0.001. (c) Kaplan–Meier
plots showing association of high LIPG expressing tumours (4 out of 200 tumours using the cut-off log2 ≥ 98th percentile) with shorter
metastasis free survival (MFS) in the Mainz cohort (GSE11121) (left) and in the combined cohort of untreated patients (16 out of
824 tumours, consisting of GSE11121, GSE2034, GSE5327, GSE6532 and GSE7390) (right). p*: p-Value of the permutation test; p:
p-Value from the log-rank test. (d) top: Representative images of LIPG IHC of 259 node-negative breast carcinomas of the tissue
microarray (TMA); scale bars: 100 μm; (d) bottom, left: barplot showing LIPG protein expression distribution in the TMA; (d) bottom,
middle: Kaplan–Meier plot of the association of LIPG protein expression (as determined by IHC in the tissue array) with metastasis free
survival (MFS). p: p-Value of the log-rank test; (d) bottom right: Association between LIPG mRNA (Affymetrix data) and LIPG protein
expression (IHC data) in the Mainz cohort. (e) Scatter plots displaying the relationship between expression of LIPG and PLIN2, and (f )
between expression of LIPG and TXNRD1 in the combined cohort of node-negative untreated breast cancer patients. The dashed lines
represent the cut-off for LIPG (log2 ≥ 98th percentile) and the median for PLIN2 and TXNRD1. The number of samples in each quadrant is
shown. P: p-Value from Fisher’s exact test. (g) Kaplan–Meier plots showing association of LIPG and PLIN2 and (h) LIPG and TXNRD1 with
MFS in each of the patient subgroups stratiﬁed according to the aforementioned cutpoints. p-Values of the log-rank test for the pairwise
comparisons are shown in the corresponding tables. (i) Proposed model: Adaptation of tumour cells to oxidative stress by LIPG: Under
normal conditions cells synthesise fatty acids (FA) de novo via FAS, which consumes NADPH. Basal levels of LIPG may supply FA as well.
Upon oxidative stress, activation of AMPK triggers a metabolic reprogramming that turns down ATP/NADPH consuming pathways such as
the de novo FAS, enabling NADPH-dependent protein repair via TXNRD1/TXN. Upregulation of LIPG along with PLIN2 and TXNRD1 occurs.
Secreted LIPG provides FA that become stored as triglycerides in PLIN2-coated lipid droplets. These support mitochondrial integrity,
possibly via lipid remodeling, and thus protect against ROS.
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stress conditions, when lipogenesis is inhibited via AMPK.
In this context, LDs accumulated by the action of LIPG fuel
and protect mitochondria from ROS, possibly superoxide
(Fig. 5i). Thus, high compensatory LIPG expression may
facilitate tumour cell survival under oxidative stress condi-
tions, which is supported by increased cell death in LIPG-
depleted cells. Second, high LIPG mRNA expression is
signiﬁcantly associated with shorter MFS of node-negative,
adjuvantly untreated breast cancer. Therefore, LIPG appears
to contribute to unfavourable prognosis, enabling adaptation
to oxidative stress.
The different experimental conditions in which we
observed LIPG upregulation, OIS, chemical hypoxia by
CoCl2, and exposure to H2O2 and rotenone are character-
ized by severe oxidative stress. This strongly supports oxi-
dative stress as a biological context in which high LIPG
expression is required for survival of tumour cells. In all
cases, increased mRNA levels of TXNRD1 accompanied the
upregulation of LIPG expression, indicating an enhanced
demand for NADPH-dependent antioxidant pathways. We
also showed in two cases that oxidative stress led to a nega-
tive regulation of de novo FAS via AMPK. This mechanism
of repression of FAS has been reported to take place under
conditions of oxidative stress to avoid consumption of
NADPH36 and was also demonstrated to occur in a model
of Ras oncogene-induced senescence in human ﬁbro-
blasts.37 Since LIPG-mediated lipid supply via extracellular
lipolysis is NADPH-independent, we propose that this
alternative pathway reduces NADPH consumption, which
then is available as a cofactor of TXNRD1 for protein repair
(Fig. 5i).
It is noteworthy that although hypoxia-induced oxidative
stress has been reported to upregulate a pathway of exogenous
FFA uptake due to a compromised de novo FAS38 our study
showed that LIPG is not upregulated by hypoxia (1%O2). This
suggests that LIPG is not essential in hypoxia-triggered lipid
accumulation under these conditions.
Our ﬁndings also indicate that FFAs supplied by LIPG
contribute to the formation of LDs. Lipid droplets have
recently been reported to protect cells against ROS.38,39
One potential mechanism is the redirection of ROS-
susceptible polyunsaturated fatty acids from the cell mem-
brane to LDs where they are shielded from peroxidation.39
Interestingly, our previous study showed that senescent
MCF-7/NeuT cells underwent a glycerophospholipid remo-
delling towards increased saturation of acyl chains, thereby
decreasing susceptibility to peroxidation.8 In this context,
LIPG-triggered LDs may support membrane lipid repair,
preserving mitochondrial integrity from ROS. Thus, in con-
trast to a reported role for LIPG in fuelling proliferation,9
Figure 5. Continued
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the present results showed a cell proliferation-independent
and previously unrecognized role of LIPG in enabling pro-
tective LDs accumulation in tumour cells. In agreement
with this hypothesis, breast tumours expressing high levels
of LIPG also expressed high levels of the oxidative stress
marker TXNRD1, and the lipid droplet marker PLIN2 and
MFS time was shorter in PLIN2 and LIPG-high as well as
in TXNRD1 and LIPG-high subgroups compared to only-
TXNRD1-high or only-PLIN2-high subgroups. The ﬁnding
that LIPG signiﬁcantly improved the likelihood ratio statis-
tics compared to models with PLIN2 or TXNRD1 alone
demonstrates the independent contribution of LIPG to
worse prognosis.
Our ﬁndings that high LIPG mRNA expression is
restricted in breast cancer and signiﬁcantly associated with
worse survival apparently contradict the study reporting a
broad expression and no signiﬁcant association between
IHC-determined LIPG and survival.9 When we performed
IHC of our TMA, using the same LIPG antibody as Slebe
and co-workers,9 we also found no association of cytoplas-
mic LIPG positivity with prognosis in our cohort, but also
no association of cytoplasmic LIPG positivity with LIPG
transcript levels. Importantly, our in vitro studies demon-
strated that LIPG mRNA levels only correlated with those
of extracellular LIPG protein and not with those of cyto-
plasmic LIPG, which may account for the remaining non-
secreted LIPG pool. Since the extracellular localization
enables LIPG to access serum lipoproteins for lipid supply
we conclude that the actively secreted LIPG protein, and
thus, as a surrogate, LIPG transcript levels represent a more
relevant measure for analysing the association with tumour
prognosis. Notably, only via this approach could LIPG’s
association with worse prognosis be uncovered. The initial
observation of LIPG’s association with shorter MFS made
in our own cohort was subsequently conﬁrmed in two
additional publicly available breast cancer cohorts. More-
over, a signiﬁcant association of high LIPG with grade
3 and with negative ER status was observed. The latter was
in agreement with a much higher LIPG expression in the
triple negative cell lines MDA-MB231 und MDA-MB468,
and in the ER-/HER2+ cell lines HCC1954 and SKBR3 than
in the ER-positive cell lines MCF-7, T47D and BT474. The
lack of signiﬁcant association of high LIPG with HER2 status
observed in tumours and in the cell lines was consistent with
our ﬁnding that LIPG is not upregulated by HER2 overex-
pression in cultured breast cancer cells. Finally, our ﬁndings
are in line with a recent study reporting expression and a
role for LIPG in metastasis of human basal-like triple-
negative breast cancer.10
In summary, integrating our in vitro experimental data
and our analysis of LIPG-expressing tumours led to the
concept that LIPG upregulation in cancer cells under oxi-
dative stress enables survival when the lipid requirement of
the cell exceeds its capacity to synthesize fatty acids de
Table 1. Univariate and multivariate Cox analysis showing association of LIPG mRNA expression with metastasis free survival (MFS) in a
combined cohort of node-negative untreated breast cancer patients (n = 824) consisting of the GSE11121 (n = 200), GSE2034, (n = 286),
Transbig (GSE6532 and GSE7390, n = 280) and GSE5327 (n = 58) cohorts
Combined cohort
Univariate Multivariate
HR p 95% CI HR p 95% CI
Age
<50 years 1.00 1.00
≥50 years 1.01 0.976 0.71–1.43 1.02 0.922 0.71–1.47
pT stage
Stage I 1.00 1.00
Stage II + III 1.32 0.114 0.93–1.87 1.18 0.370 0.82–1.71
Grade
Grade 1 + 2 1.00 1.00
Grade 3 1.93 <0.001 1.36–2.75 1.70 0.013 1.12–2.58
ER status
Negative 1.00 1.00
Positive 0.74 0.031 0.56–0.97 1.00 0.987 0.64–1.57
HER2 status
Negative 1.00 1.00
Positive 1.13 0.468 0.81–1.58 1.20 0.465 0.74–1.93
LIPG 1.59 0.002 1.18–2.15 1.95 0.002 1.26–2.99
Abbreviations: HR, hazard ratio; p, p-value (unadjusted); CI, confidence interval.
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novo, or when de novo lipogenesis is repressed by ROS.
Although cancer cells have generally high ROS levels, these
levels further increase under a harsh tumour microenviron-
ment, nutrient deprivation or upon matrix detachment.40,41
Thus, metabolic adaptation to these conditions via LIPG upre-
gulation may be a crucial event determining adverse progres-
sion, as suggested by the observation that high LIPG expression
is associated with shorter MFS.
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